US Drug Recall Register

FDA Drug Recalls

14,450 recalls · Class II, newest first

Class II · Moderate risk Terminated

Pearson Quality

Reason CGMP deviations: the bulk product was rejected by the Quality Unit after routine inspection of the mixing vessel showed scratches on the sides and bottom of the mixing vessel. Product was to be rejected but was inadvertently released and shipped to customers.

Keystone Industries D-0144-2025
Class II · Moderate risk Terminated

Burkhart

Reason CGMP deviations: the bulk product was rejected by the Quality Unit after routine inspection of the mixing vessel showed scratches on the sides and bottom of the mixing vessel. Product was to be rejected but was inadvertently released and shipped to customers.

Keystone Industries D-0143-2025
Class II · Moderate risk Terminated

Health-Tec

Reason CGMP deviations: the bulk product was rejected by the Quality Unit after routine inspection of the mixing vessel showed scratches on the sides and bottom of the mixing vessel. Product was to be rejected but was inadvertently released and shipped to customers.

Keystone Industries NDC 69634-021-30 D-0142-2025
Class II · Moderate risk Terminated

Patterson Dental

Reason CGMP deviations: the bulk product was rejected by the Quality Unit after routine inspection of the mixing vessel showed scratches on the sides and bottom of the mixing vessel. Product was to be rejected but was inadvertently released and shipped to customers.

Keystone Industries NDC 50227-1002-3 D-0141-2025
Class II · Moderate risk Terminated

Dental City

Reason CGMP deviations: the bulk product was rejected by the Quality Unit after routine inspection of the mixing vessel showed scratches on the sides and bottom of the mixing vessel. Product was to be rejected but was inadvertently released and shipped to customers.

Keystone Industries D-0140-2025
Class II · Moderate risk Terminated

Primo

Reason CGMP deviations: the bulk product was rejected by the Quality Unit after routine inspection of the mixing vessel showed scratches on the sides and bottom of the mixing vessel. Product was to be rejected but was inadvertently released and shipped to customers.

Keystone Industries D-0139-2025
Class II · Moderate risk Terminated

M&S Dental Supply Co LLC.

Reason CGMP deviations: the bulk product was rejected by the Quality Unit after routine inspection of the mixing vessel showed scratches on the sides and bottom of the mixing vessel. Product was to be rejected but was inadvertently released and shipped to customers.

Keystone Industries D-0138-2025
Class II · Moderate risk Terminated

Gelato

Reason CGMP deviations: the bulk product was rejected by the Quality Unit after routine inspection of the mixing vessel showed scratches on the sides and bottom of the mixing vessel. Product was to be rejected but was inadvertently released and shipped to customers.

Keystone Industries NDC 68400-352-30 D-0137-2025
Class II · Moderate risk Ongoing

Duloxetine Delayed-Release Capsules

Reason CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit

Amerisource Health Services LLC NDC 68001-415-08 D-0101-2025
Class II · Moderate risk Ongoing

Duloxetine Delayed-Release Capsules

Reason CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit

Amerisource Health Services LLC NDC 68001-414-04 D-0100-2025
Class II · Moderate risk Ongoing

Duloxetine Delayed-Release Capsules

Reason CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit

Amerisource Health Services LLC NDC 68001-413-06 D-0099-2025
Class II · Moderate risk Ongoing

Kissable Diabetics Foot Cream

Reason CGMP Deviations: lack of adequate release testing.

Brands International Corporation D-0205-2025
Class II · Moderate risk Ongoing

Venofer

Reason Presence of Particulate Matter: Potential for glass delamination from the vials.

American Regent, Inc. D-0082-2025
Class II · Moderate risk Ongoing

Venofer

Reason Presence of Particulate Matter: Potential for glass delamination from the vials.

American Regent, Inc. D-0081-2025
Class II · Moderate risk Ongoing

Venofer

Reason Presence of Particulate Matter: Potential for glass delamination from the vials.

American Regent, Inc. D-0080-2025
Class II · Moderate risk Ongoing

Docusate Sodium 250 mg

Reason cGMP Deviations: Observations were made that some blister card-foils were separating from the blister cavity.

Safecor Health, LLC NDC 48433-101-01 D-0060-2025
Class II · Moderate risk Ongoing

Calcium Carbonate Chewable 500 mg

Reason cGMP Deviations: Observations were made that some blister card-foils were separating from the blister cavity.

Safecor Health, LLC NDC 48433-106-01 D-0059-2025
Class II · Moderate risk Ongoing

Aspirin Chewable tablet 81 mg

Reason cGMP Deviations: Observations were made that some blister card-foils were separating from the blister cavity.

Safecor Health, LLC NDC 48433-129-01 D-0058-2025
Class II · Moderate risk Ongoing

Vitamin B1

Reason cGMP Deviations: Observations were made that some blister card-foils were separating from the blister cavity.

Safecor Health, LLC NDC 48433-108-01 D-0057-2025
Class II · Moderate risk Ongoing

Vitamin D3

Reason cGMP Deviations: Observations were made that some blister card-foils were separating from the blister cavity.

Safecor Health, LLC NDC 48433-104-01 D-0056-2025
Class II · Moderate risk Ongoing

Levothyroxine Sodium Tablets

Reason Subpotent drug

Accord Healthcare, INC. NDC 16729-449-17 D-0076-2025
Class II · Moderate risk Ongoing

Cinacalcet Tablets

Reason cGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit

Aurobindo Pharma USA Inc NDC 65862-833-30 D-0079-2025
Class II · Moderate risk Ongoing

Cinacalcet Tablets

Reason cGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit

Aurobindo Pharma USA Inc NDC 65862-832-30 D-0078-2025
Class II · Moderate risk Ongoing

Cinacalcet Tablets

Reason cGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit

Aurobindo Pharma USA Inc NDC 65862-831-30 D-0077-2025